Anda di halaman 1dari 2

Sabutamol Introduction: Salbutamol tablets belong to a group of medicines called selective beta-2-adrenergic agonists, which can be used to relax

the muscles of the airways and womb. Mechanism of action: Salbutamol (beta 2 agonist): Stimulates adenyl cyclase. Theophylline (xanthine derivative): Inhibits phosphodiesterase. Indications: Salbutamol tablets are indicated for the relief of bronchospasm in asthma, chronic bronchitis, emphysema and other conditions associated with airways obstruction, and for prevention of asthma attack triggered by allergic exposure or exercise. Dosage: Adults: 2-4 mg, three or four times daily. Children (7-12 years): 2 mg, three or four times daily. Children (2-6 years): 1-2 mg, three or four times daily. Side effects: The adverse reactions to salbutamol are similar in nature to reactions to other sympathomimetic agents. The most frequent adverse reactions to salbutamol are nervousness, tremor, headache, tachycardia, and palpitations. Less frequent adverse reactions are muscle cramps, insomnia, nausea, weakness, dizziness, drowsiness, flushing, restlessness, irritability, chest discomfort, and difficulty in micturition. Rare cases of urticaria, angio-oedema, rash, bronchospasm, and oropharyngeal oedema have been reported after the use of salbutamol. It can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx. Precautions: Salbutamol, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressures have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Salbutamol may produce significant hypokalaemia in some patients, possibly through intracellular shunting, and this has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Cardiovascular Effects: Salbutamol can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of salbutamol tablets at recommended doses, if they occur, the drug may need to be discontinued. salbutamol should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of salbutamol tablets than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment; e.g., corticosteroids. Use of Anti-Inflammatory Agents: The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents; e.g., corticosteroids. Paradoxical Bronchospasm: Salbutamol tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, salbutamol sustained-release tablets should be discontinued immediately and alternative therapy instituted. Rarely, erythema multiforme and StevensJohnson syndrome have been associated with the administration of oral salbutamol in children. Pregnancy: Pregnancy Category C . There are no adequate and well-controlled studies in pregnant women. Salbutamol should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Lactation: It is not known whether salbutamol is excreted in human milk. Because of the potential for tumorigenicity shown for salbutamol in animal studies, a decision should be made whether to discontinue lactation or to discontinue the drug, taking into account the importance of the drug to the mother. Paediatric Use: The safety and effectiveness of salbutamol have been established in paediatric patients, 6 years of age or older. Use of salbutamol in these age groups is supported by evidence from adequate and well-controlled studies of salbutamol sustained-release tablets in adults; the likelihood that the disease course, pathophysiology, and the drug`s effect in paediatric and adult patients are substantially similar. Contraindications: Salbutamol tablets are contraindicated in patients who have shown hypersensitivity to any of its constituent. How supplied: Customized as per request.